Key Takeaways for California Dentists
- DSO equity rollovers typically convert 15–40% of sale proceeds into illiquid ownership in the buyer’s parent company, with the rest paid in cash at closing.
- California’s 2025–2026 CPOD rules require all rollover equity to sit outside the dental PC through an MSO or holding-company structure that preserves dentist ownership and clinical control.
- Competition among multiple qualified buyers can be one of the most effective ways to protect rollover valuation and avoid unfavorable liquidation preferences or quiet repricing.
- Second-bite liquidity often occurs 5–7 years after closing, and dilution, platform leverage, and exit-multiple risk can materially reduce the realized value of rolled equity.
- McLerran & Associates uses a competitive bid process and multi-year financial modeling to help California sellers compare and negotiate DSO rollover offers. Request a confidential cash-versus-equity review for your practice.
Cash Versus Equity: Typical 2026 Deal Structures in California
Most 2026 dental DSO transactions in California use 60–85% cash at closing and 15–30% rollover equity, with any remainder structured as an earnout. The exact mix often shifts with practice size and buyer type. Smaller solo practices usually see rollover requirements at the lower end of that range. Larger regional groups or platform-tier practices with multiple locations and institutional-grade EBITDA can face rollover expectations closer to 25–35%. For the largest practices, private-equity majority recapitalizations can push the rollover component toward 40%.
California sellers also face a consolidation-focused DSO market rather than a new-platform-creation phase. EBITDA multiples for quality multi-site assets often range from 8× to 14×, and buyers are scrutinizing platform stability before committing to recapitalization timelines. Your first step is to understand where your practice fits in that spectrum and what cash-versus-equity mix can be realistic for your specific revenue and EBITDA profile.
How Buyers Value Rollover Equity in DSO Deals
Buyers typically price rollover equity at the same valuation multiple they pay for the cash portion of your practice at closing. The headline concept sounds simple, yet the fine print can be some of the most important detail in the deal. Some buyers attempt to reprice rollover equity at a lower multiple or attach senior liquidation preferences, which means their preferred equity gets paid before your common equity at exit. Quietly accepting those terms can reduce what your rollover is worth at the second bite.
Rollover equity can also sit at two different levels. Joint-venture equity ties your stake to your specific practice or a regional cluster. It may provide interim distributions, which can support income, but it usually has a lower upside ceiling. Holding-company equity ties your stake to the entire DSO platform. It typically does not provide interim distributions, yet it can have a higher ceiling if the platform exits at a premium multiple. These instruments are not equivalent. Comparing offers that mix the two usually requires side-by-side financial modeling rather than a simple headline number comparison.
Competition among buyers can be one of the clearest ways to protect rollover valuation. When several well-qualified buyers bid at the same time, no single buyer can quietly reprice your equity or impose unfavorable preferences without risking the loss of the deal. McLerran & Associates runs a structured, auction-like bid process that typically lasts 45–60 days and often produces around 10 offers. That process creates competitive tension and helps control the narrative around your EBITDA from the first conversation through the signed letter of intent.
Explore how a structured auction could strengthen your rollover terms with McLerran & Associates.
Second-Bite Timing and Liquidity Risk in Rollover Equity
Once you secure favorable rollover terms through competition, the next key issue is when and how that equity can convert back to cash. The “second bite” refers to the moment your rollover equity is monetized, usually when the DSO platform is sold or recapitalized by its private equity sponsor. That event has historically occurred 5–7 years after closing for many platforms, although some move faster and others slower. You generally do not control the timing.
Several risks can compound during that holding period. Dilution risk arises when future capital raises reduce your ownership percentage. Management incentive plans can grant 10–15% of platform equity to the management team, which further dilutes rollover holders. Leverage risk comes from platform-level debt that sits ahead of your rollover equity in the capital structure. If financing markets tighten and a recapitalization is delayed, your equity has no guaranteed floor. Platform performance risk also matters. Only the cash-at-close portion of your deal is guaranteed. The realized value of the rollover depends entirely on the DSO’s growth and the exit multiple.
Strong platform performance can allow rollover equity to return 2–4× the rolled amount. Weak performance can lead to a return below face value. One practical framework for risk-adjusting rollover equity discounts it to 60–70% of face value on average to reflect illiquidity and exit uncertainty. That haircut can be meaningful when rollover represents 20–40% of your total proceeds.
California CPOD Rules and Rollover Equity Structures
California’s Corporate Practice of Dentistry doctrine restricts non-dentists from owning or controlling a dental practice. California codified and reinforced these rules in 2025 through SB 351, and the California Attorney General has increased enforcement through 2026 settlements. Those settlements imposed civil penalties and required structural changes for DSO operators whose management agreements crossed into clinical control.
For DSO equity rollover structures, these rules mean the rollover cannot give a lay investor or management entity direct ownership in the dental practice entity. All equity exposure must sit outside the professional dental corporation, usually through a Management Services Organization structure that preserves dentist ownership and clinical control. Under the Moscone-Knox Professional Corporation Act, at least 51% of shares in a California dental corporation must be held by licensed dentists, with up to 49% held by listed allied licensed professionals. Share transfers are restricted to maintain that balance.
The checklist below summarizes core California PC compliance requirements for DSO rollover structures.
- The dental PC must be owned entirely by one or more California-licensed dentists. Non-dentist ownership at the PC level, including private equity funds or management companies, is not permitted.
- The MSO may handle payroll, bookkeeping, marketing, and vendor relationships, but cannot control treatment planning, hiring or firing of clinical staff, billing and coding decisions, or scheduling.
- Equity rollover consideration must flow through the holding company or MSO layer, not through the PC itself.
- MSO contract terms that govern equity rights, transfer mechanics, and exit provisions must avoid functioning as a backdoor transfer of control over the PC, consistent with the California Attorney General’s 2026 enforcement positions.
- Assignable options to acquire ownership interests in the PC, and management fees based on practice revenue or profits, currently sit among the highest-risk provisions under California enforcement.
- Any unitholder agreement that governs your rollover equity should be reviewed by a California-licensed attorney with CPOD experience before you sign.
Key Unitholder Agreement Terms That Affect Your Outcome
The unitholder or operating agreement you sign at closing governs your entire relationship as a minority equity holder during the hold period. These agreements define voting rights, distribution terms, information access, and treatment of your equity when the platform eventually sells. Because these definitions shape how and when you get paid, certain provisions can have an outsized impact on your realized return. The provisions below can be some of the most consequential to negotiate.
- Tag-along rights: These rights allow you to participate on identical terms if the majority owner sells its stake. They help you avoid being left with an unknown new controlling owner.
- Drag-along rights: These rights are standard in private equity deals and allow the sponsor to require you to sell in a future exit. You can negotiate a minimum return threshold, such as 1.5× your rolled amount, or a defined valuation floor before drag-along can be triggered.
- Anti-dilution protections: Without these protections, unfavorable follow-on equity issuances can dilute your ownership percentage without your consent. Weighted-average anti-dilution is more common. Full ratchet protection is stronger but less common.
- Information rights: You can negotiate quarterly financial statements, annual audited financials, and at least board observer access. Without information rights, you remain a passive minority holder with limited visibility into platform health.
- Vesting and forfeiture: Vesting provisions may require you to forfeit equity if you terminate employment before specified dates. You can negotiate immediate vesting on a change of control and “good reason” termination rights.
- Put options: A put option gives you the right to require the platform to buy back your equity at a defined formula. This feature can create a forced liquidity mechanism if the platform has not exited by year 6 or 7.
- Liquidation preferences: Many deals feature a 1× liquidation preference plus an 8% annual preferred return that must be paid to the private equity firm before common equity holders receive proceeds at exit. You should understand exactly where your equity sits in that waterfall.
High-Level Tax Treatment of Rollover Equity
Federal tax deferral on rollover equity can occur through two main mechanisms. Under Internal Revenue Code (IRC) Section 351, you may defer gain when you contribute your practice stock to a new corporation in exchange for equity, as long as the transferors collectively control at least 80% of the new entity immediately after the transfer. The cash portion you receive at closing is taxable as “boot,” which is a tax term for non-stock consideration received in an otherwise tax-deferred exchange. Under IRC Section 721, a similar deferral can apply when the acquiring entity is structured as a partnership or an LLC taxed as a partnership.
California’s tax treatment of Section 351 transactions can differ from federal rules in certain respects. Sellers may face distinct state capital gains tax implications for the rollover equity portion, which usually calls for a separate California tax analysis before closing. That analysis can materially affect your after-tax outcome and often warrants early coordination with a CPA who has experience in California dental transactions.
At the second-bite exit, when your rollover equity is ultimately sold, gain is generally taxed at long-term capital gains rates if the holding period exceeds one year. Under IRC Section 1223, the holding period of your original practice equity can carry over to the holding period of your rollover equity, which can be a meaningful advantage. This discussion is educational only and does not constitute tax advice. You should consult your CPA and transaction attorney before structuring any rollover.
When to Negotiate Harder and When to Walk Away
Not every DSO offer with a rollover component deserves a counter. Some offers justify aggressive negotiation, while others reveal structural issues that can be difficult to fix. The decision framework below helps you separate negotiable problems from potential deal-breakers.
Consider negotiating harder when:
- The rollover is priced at a lower multiple than the cash portion or carries senior liquidation preferences that subordinate your common equity.
- The unitholder agreement omits tag-along rights, anti-dilution protections, or meaningful information rights.
- The DSO’s audited financials show declining same-store revenue or EBITDA compression at existing locations.
- The private equity sponsor is late in its fund cycle, which can limit runway for a favorable exit before the fund must return capital.
- Vesting provisions would cause you to forfeit equity if you leave before year 5 without a clearly defined “good reason” carve-out.
Consider walking away when:
- The platform carries debt levels that materially exceed its EBITDA, leaving limited cushion for your equity in a stress scenario.
- The DSO cannot or will not provide audited financials, prior-round dilution history, or the full distribution waterfall.
- California CPOD compliance review reveals MSO contract terms that could expose your dental license to Dental Board investigation.
- The rollover percentage exceeds 35% and no put option or forced-liquidity mechanism is available after year 6.
- A competitive process has produced better-structured offers from other well-qualified buyers.
Five Questions to Ask About Your Rollover
- At what valuation multiple is my rollover equity priced, and does it match the multiple paid for the cash portion? Any discount to the cash-portion multiple can quietly reduce your second-bite upside before the deal closes.
- What is the platform’s current debt-to-EBITDA ratio, and how does that leverage affect my equity’s position in the capital structure? Platform debt ranks ahead of your common equity at exit.
- Where is the private equity sponsor in its fund cycle, and what recapitalization timeline are they targeting? A sponsor in year 7 of a 10-year fund usually has less flexibility to wait for an optimal exit than one in year 3.
- What anti-dilution, tag-along, and information rights are included in the unitholder agreement, and are they enforceable under California law? Protections that appear strong on paper can be weakened by carve-outs or California-specific enforceability issues.
- Has the platform provided audited financials, a history of prior equity raises and dilutions, and the full distribution waterfall? Accepting rollover equity without this diligence can resemble buying stock in a company whose books you have never seen.
20%, 30%, and 40% Rollover Scenarios: After-Tax Cash-Flow Snapshot
The table below illustrates how different rollover percentages can affect realized proceeds on a hypothetical $5 million practice sale, using a 3-, 5-, and 7-year second-bite horizon. All figures are illustrative and assume a 2× second-bite return on the rolled amount, which sits near the middle of reported second-bite ranges of 2–4× for well-performing platforms. Risk-adjusted rollover values apply a 60–70% realization discount to reflect illiquidity and exit uncertainty. You should consult your CPA for deal-specific after-tax modeling.
| Rollover % | Cash at Close (of $5M) | Rolled Amount | Risk-Adjusted Rollover Value (60–70% of face) |
|---|---|---|---|
| 20% (standard midpoint) | $4,000,000 | $1,000,000 | $600,000–$700,000 (realized at year 5–7 exit) |
| 30% (regional group range) | $3,500,000 | $1,500,000 | $900,000–$1,050,000 (realized at year 5–7 exit) |
| 40% (PE majority recap range) | $3,000,000 | $2,000,000 | $1,200,000–$1,400,000 (realized at year 5–7 exit) |
This comparison highlights a core tension. Higher rollover percentages reduce guaranteed cash at close while increasing exposure to platform performance risk. A 40% rollover on a $5 million deal leaves $2 million locked in an illiquid minority position for potentially 5–7 years, which can represent a large share of net worth for many practice owners. Multi-year, multi-structure financial modeling that incorporates California’s tax rules and your specific EBITDA profile can be one of the clearest ways to compare these scenarios.
Frequently Asked Questions
This FAQ section addresses common questions California dentists raise when they first encounter DSO rollover structures.
What are the main disadvantages of a DSO equity rollover for a California dental practice owner?
The primary disadvantages often include illiquidity, dilution risk, and state tax considerations for rollover equity. Your rolled equity typically remains locked up for 5–7 years with no ability to sell on your own timeline. Future capital raises by the DSO can reduce your ownership percentage, and management incentive plans can further dilute rollover holders. California tax rules for these transactions may differ from federal treatment in certain ways. As a minority holder in a private company, you also have limited visibility into platform performance unless you negotiate robust information rights at the outset.
How does the second-bite mechanism actually work in a dental DSO deal?
When you roll equity into a DSO, you become a minority shareholder in the DSO’s parent company or holding entity. Your equity is monetized when that platform is sold or recapitalized, which usually aligns with the private equity sponsor’s fund timeline rather than your personal schedule. At that second exit, your shares are sold at whatever multiple the new buyer pays for the platform. Strong platform growth can produce a multiple of the amount you rolled. Weak performance can produce a return below face value. The typical second-bite window usually matches the private equity sponsor’s fund timeline and, as discussed earlier, often falls in the 5–7 year range, although this can vary with sponsor strategy and market conditions.
Can a DSO directly own my California dental practice as part of a rollover structure?
No. California’s Corporate Practice of Dentistry doctrine prohibits non-dentists, including private equity funds and management companies, from owning or controlling a dental practice. Your dental professional corporation must remain owned by a California-licensed dentist. DSO equity rollover structures in California must route all non-dentist equity exposure through a Management Services Organization or holding company layer outside the PC. The MSO can handle administrative functions but cannot control clinical decisions, hiring of clinical staff, or billing and coding. California enforcement of these rules has intensified through 2026, so any rollover structure should be reviewed by a California attorney with CPOD experience before you sign.
What is the difference between joint-venture equity and holding-company equity in a DSO rollover?
Joint-venture equity ties your ownership stake to a specific practice or regional cluster within the DSO. It usually provides interim distributions from that entity’s profits, which can support income during the hold period. The tradeoff is a lower upside ceiling because your return is limited to that subset of the platform. Holding-company equity ties your stake to the entire DSO parent. It typically does not provide interim distributions, yet it can offer higher upside if the platform exits at a premium multiple. Neither structure works better in every situation. The right choice often depends on your income needs during the hold period, your confidence in the platform’s overall growth, and the specific terms in your unitholder agreement.
How does McLerran & Associates help California practice owners evaluate DSO rollover offers?
McLerran & Associates begins with a diligence-grade, CPA-led EBITDA analysis before any offer goes to market. That foundation helps ensure the numbers that anchor your valuation can withstand buyer scrutiny and are less likely to be renegotiated down later. From there, the firm creates competition among multiple qualified buyers through the structured process described earlier, so no single DSO can quietly reprice your rollover equity or impose unfavorable terms without risking the deal. McLerran also prepares multi-year, multi-structure financial forecasts that model your after-tax cash across different rollover percentages, second-bite timelines, and California tax scenarios. Those comparisons can give you a clearer view than a single headline number. The firm works exclusively on the sell-side, so its incentives align with you rather than the buyer.
Conclusion: Treat Rollover Equity as a Separate Investment Decision
A DSO equity rollover can become a meaningful wealth-building tool for California dental practice owners, yet it can also introduce significant financial risk. Outcomes often depend on how the structure is negotiated, how the platform performs, and how California’s compliance requirements are satisfied. The rollover percentage, equity level, unitholder agreement, and tax treatment each matter. These variables usually work best when evaluated together and compared across several buyers, not in isolation or against a single offer.
McLerran & Associates has guided practice owners through more than 2,000 successful transactions and approximately $2 billion in closed volume, with a team that brings over 100 years of collective dental-industry experience. The firm’s Los Angeles office, led by Steven Au, works directly with California practice owners who are weighing DSO affiliation decisions. That work includes controlling the narrative around EBITDA, creating competition among well-qualified buyers, and modeling the real after-tax outcome across every structure before any letter of intent is signed.
